Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.37 |
| ▸ | NOS2 | P35228 | 3/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL27856553 | 0.81 | — | — | |
| Carbamic Acid SCHEMBL28864494 | 0.79 | EPHX1 (0.42) | NOS2EPHX1TDP1CYP1A2NOS3 | |
| SCHEMBL2368 | 0.75 | — | — | |
| SCHEMBL19957485 | 0.75 | NOS2 (0.37) | MGLLNOS2CTSK | |
| Bicarbonate SCHEMBL10617200 | 0.73 | — | — | |
| Propene SCHEMBL6040499 | 0.73 | — | — | |
| Cyclopropane SCHEMBL9026881 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL1937438 | 0.71 | — | — | |
| Ammonia Solution, Strong SCHEMBL3799540 | 0.71 | — | — | |
| Cyclohexane SCHEMBL6972653 | 0.71 | TSHR (0.46) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| CN-115414480-A | Dianhydrogalactitol in combination with radiation for treatment of non-small cell lung cancer and glioblastoma multiforme | 德玛医药 | 2022-12-02 | — | — | CN | disclosed |
| CN-106659765-B | Use of dianhydrogalactitol and analogs or derivatives thereof for treating non-small cell lung cancer and ovarian cancer | 德玛医药 | 2021-08-13 | — | — | CN | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| US-20160045502-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2016-02-18 | — | — | US | disclosed |
| US-7071158-B2 | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20010049349-A1 | Antioxidant enhancement of therapy for hyperproliferative conditions | CRABTREE ACQUISITION CO, LLC | 2001-12-06 | — | — | US | disclosed |
| EP-0433393-B1 | TREATMENT OF DAMAGED BONE MARROW AND DOSAGE UNITS THEREFOR | UNIV ROCHESTER (US) | 1995-03-15 | — | — | EP | disclosed |
| EP-0433393-A4 | TREATMENT OF DAMAGED BONE MARROW AND DOSAGE UNITS THEREFOR | — | 1992-01-15 | — | — | EP | disclosed |
| US-5035878-A | Reversing bone marrow damage resulting from chemotherapy | UNIVERSITY OF ROCHESTER (US) | 1991-07-30 | — | — | US | disclosed |
| EP-0433393-A1 | TREATMENT OF DAMAGED BONE MARROW AND DOSAGE UNITS THEREFOR. | UNIV ROCHESTER (US) | 1991-06-26 | — | — | EP | disclosed |
| US-4938949-A | Combatting side effects of anticancer drugs with dithiocarbamates | UNIVERSITY OF NEW YORK (US) | 1990-07-03 | — | — | US | disclosed |
| WO-1990002550-A1 | TREATMENT OF DAMAGED BONE MARROW AND DOSAGE UNITS THEREFOR | UNIVERSITY OF ROCHESTER (US) | 1990-03-22 | — | — | WO | disclosed |
| US-4594238-A | Administering platinum compound; then platimun binding compound | REGENTS OF UNIVERSITY OF MINNESOTA (US) | 1986-06-10 | — | — | US | disclosed |
| US-4581224-A | ANTITUMOR, ANTRICARCINOGENIC AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1986-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | MGLL 4219/4885NOS2 2834/4885EPHX1 1037/4885 |
| US-20160045502-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | MGLL 4219/4885NOS2 2834/4885EPHX1 1037/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | MGLL 2397/4885NOS2 3492/4885EPHX1 3224/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | MGLL 2397/4885NOS2 3492/4885EPHX1 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.